Seeking Alpha

Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an...

Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an 18% premium. OMRI's lead product is its fibrin blood-clotting pad, which controls surgical bleeding, and which it claims is superior to JNJ's Surgicel. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs